These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 38476294)
1. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis. Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294 [TBL] [Abstract][Full Text] [Related]
2. Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis. Shen X; Yang J; Qian G; Sheng M; Wang Y; Li G; Yan J Front Oncol; 2024; 14():1391724. PubMed ID: 38826783 [TBL] [Abstract][Full Text] [Related]
3. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis. Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419 [TBL] [Abstract][Full Text] [Related]
4. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis. Dang S; Li X; Liu H; Zhang S; Li W Cancer Med; 2024 Apr; 13(7):e7119. PubMed ID: 38553943 [TBL] [Abstract][Full Text] [Related]
5. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. Lei Q; Yan X; Zou H; Jiang Y; Lai Y; Ung COL; Hu H Discov Oncol; 2022 Sep; 13(1):95. PubMed ID: 36171533 [TBL] [Abstract][Full Text] [Related]
7. Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis. Zheng Y; Dong H; Yu Y; Hu Z; Xue C; Zhang X; Cui H Int Immunopharmacol; 2023 Oct; 123():110785. PubMed ID: 37598630 [TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis. Liang X; Chen X; Li H; Li Y Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447 [TBL] [Abstract][Full Text] [Related]
9. A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma. Wang B; Hao X; Yan J; Li X; Zhao M; Han T J Transl Int Med; 2024 Jun; 12(3):225-243. PubMed ID: 39081283 [TBL] [Abstract][Full Text] [Related]
10. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis. Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682 [TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958 [TBL] [Abstract][Full Text] [Related]
13. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis. Chen CY; Huang CH; Chen WC; Huang MS; Wei YF Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121 [TBL] [Abstract][Full Text] [Related]
14. Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review. Xu T; Liu Y; Lu X; Liang J Front Immunol; 2022; 13():1039020. PubMed ID: 36439117 [TBL] [Abstract][Full Text] [Related]
15. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer. Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW Front Immunol; 2021; 12():760737. PubMed ID: 34925331 [TBL] [Abstract][Full Text] [Related]
16. Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis. Xie R; Wu J; Shang B; Bi X; Cao C; Guan Y; Shi H; Shou J Cancer Innov; 2022 Dec; 1(4):293-304. PubMed ID: 38089086 [TBL] [Abstract][Full Text] [Related]
17. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759 [TBL] [Abstract][Full Text] [Related]
18. Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials. Hou J; Xie R; Zhang Z; Liu Q; Xiang Q; Cui Y Front Pharmacol; 2023; 14():1163971. PubMed ID: 37033653 [No Abstract] [Full Text] [Related]
19. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508 [TBL] [Abstract][Full Text] [Related]
20. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. Zheng J; Huang B; Xiao L; Wu M; Li J Front Oncol; 2022; 12():821626. PubMed ID: 36568203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]